Tarsus Pharmaceuticals, Inc. TARS Accrued Liabilities & Other
Accrued Liabilities & Other at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s accrued liabilities & other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s accrued liabilities & other?
- Tarsus Pharmaceuticals, Inc. (TARS) reported accrued liabilities & other of $110.85M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s accrued liabilities & other changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s accrued liabilities & other increased by 45.1% year-over-year, from $76.38M to $110.85M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s accrued liabilities & other?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s accrued liabilities & other has grown at a 87.8% compound annual growth rate (CAGR), from $4.35M to $101.53M.
- What does accrued liabilities & other mean?
- Combined accrued expenses and miscellaneous current liabilities not classified in specific categories.